Author links open overlay panel V. Discontinuation sensitivity analysis Applying the sensitivity analysis discontinuation definition, higher levels of discontinuation were observed for all three treatment groups , Applying all the exclusion criteria, calcitriol-alfa, paricalcitol and cinacalcet patients remained.
|Date Added:||1 November 2014|
|File Size:||59.36 Mb|
|Operating Systems:||Windows NT/2000/XP/2003/2003/7/8/10 MacOS 10/X|
|Price:||Free* [*Free Regsitration Required]|
This is a near-universal observation, reflecting the real-life challenges in this regard, where correcting one parameter often represents a trade-off against control of another. In conditions of daily clinical practice, attaining and maintaining recommended biochemical control of sHPT appears to be more frequently achievable with cinacalcet than with activated vitamin D compounds. No major clinical history differences were apparent.
Following discontinuation main definition; Fig. Development and validation of a predictive mortality risk score from a European hemodialysis cohort.
The greater observed persistence to cinacalcet compared to AVDs might relate to clinician preference or the lack of a suitable alternative in patients uncontrolled on AVDs treatment alone. Following discontinuation, the evolution of laboratory parameters differed by treatment modality: Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Hiperparatiroidismo secundario funcional en los gatos 
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Mortality risk among hemodialysis patients receiving different vitamin D analogs.
Factores que influyen en el grado de respuesta a cinacalcet. The temporal persistence patterns differed markedly Fig.
Patient characteristics by treatment type Baseline characteristics at initiation Large geographical differences were observed in patients initiating calcitriol-alfa, paricalcitol and cinacalcet treatment Table 1probably related to differing drug access and reimbursement policies. Clinicians appear to secunrario to treatment guidelines, although goal achievement is poor.
Hiperparatiroidismo secundario funcional en los gatos
Median percentage change from baseline was presented to reflect the skewed distribution of these values. Increases in mean calcium were higher for paricalcitol than for calcitriol-alfa patients in the 6 months post-initiation.
The hiperparatidoidismo associated with niperparatiroidismo did not show any effect on the degree of response. Am J Kidney Dis ; Consistent control of mineral and bone disorder in incident hemodialysis patients. J Am Soc Nephrol ;15 3: Originales Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care hemodialysis network: Nephron Clin Pract ; Nevertheless, the pattern of paricalcitol non-persistence main definition was no different from the exclusively oral calcitriol-alfa group, suggesting that, for AVDs at least, treatment discontinuation was mainly clinician-led.
Cinacalcet patients were often prescribed concomitant AVDs. Uncorrected iPTH concentrations were used. International Symposium on Home Hemodialysis. Ther Apher Dial ;11 Suppl 1: Clin Nephrol ;71 2: Whilst post-initiation laboratory trajectories have been described previously, as outlined above, this is possibly the first study to describe in detail non-persistence to sHPT treatments and the evolution of laboratory parameters post-discontinuation.
Drug discontinuation may be patient- or physician-led and it was impossible to determine in this study which were patient decisions, based on drug intolerance or pill fatigue, and which were medical decisions based on overcorrection of PTH levels all treatment groupsundesirable increases in calcium and phosphate levels mostly with AVDs or undesirable decreases in calcium levels with cinacalcet.
Kidney Int ;68 4: The effect of calcitriol, paricalcitol and a calcimimetic on extraosseous calcifications in uremic rats. Depression and nonadherence hlperparatiroidismo mortality in hemodialysis treated end-stage renal disease, patients.